Do you want to read an article? Please log in or register.
Effect of Nirsevimab as a Primary Preventive Strategy on the Incidence, Severity, and Viral Etiology of Bronchiolitis: A Four-Year Observational Study
Further Publications
Related content
Pulmonary Fibrosis
LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis
J Cyst Fibros
Vega-Hernandez G, MacGregor G, Wilfin A, Adams F, Haugh C, Baxter CA, Wöhling H, Clarke SL, Charman SC, Carr SB
doi: 10.1016/j.jcf.2025.04.012
RECOMMENDED
Asthma
Long-Term Clinical Remission on Benralizumab Treatment in Severe Eosinophilic Asthma: A Four-Year Real-Life Study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Quarato CMI, Tondo P, Lacedonia D, Soccio P, Pescatore D, Baccellieri ML, Lepore G, Foschino Barbaro MP, Scioscia G
doi: 10.3390/jcm14062075
RECOMMENDED
Pulmonary FibrosisBronchi
Effect of elexacaftor-tezacaftor-ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med
Sermet-Gaudelus I, Letierce A, Berteloot L, Bonnel AS, Chen Y, Makani P, Kelly-Aubert M, Kanoun F, Penalva L, Bouleghem N, Bihouee T, Bui S, Corvol H, Houdouin V, Mittaine M, Tatopoulos A, Weiss L, Wizla N, Kapel N, Bessou A, Tiddens HAWM, Caudri D, Reix P, Marguet C, MODUL-CF study group
doi: 10.1016/S2213-2600(25)00248-6
RECOMMENDED
Asthma
A real-world study to evaluate effectiveness of mepolizumab in treating severe asthma in Taiwan (REMIT)
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Ther Adv Respir Dis
Cheng SL, Lin SM, Peng CK, Chan MC, Shen SY, Kuo PH, Lai CH, Lan CC, Chen CY, Lin CH, Liao KM, Feng PH, Wu JT, Wei YF, Xu X, Alfonso-Christancho R, Lai T, Navarro A, Milea D, Perng DW
doi: 10.1177/17534666241308406
Further Publications
Ten-Year outcomes of transcatheter versus surgical aortic valve replacement: extended follow-up from the OBSERVANT study
Eur J Cardiothorac Surg
Costa G, Barbanti M, Rosato S, Badoni G, Biancari F, Tatari M, Baglio G, D'Errigo P, OBSERVANT Research Group
doi: 10.1093/ejcts/ezaf476
Asthma
Effectiveness of Mepolizumab in Patients with OCS-Dependent Severe Asthma: A Real-World Study
Adv Ther
Bavbek S, Al-Ahmad M, Samaha H, Kathuria PC, Fernandez P, Al Busaidi N, Ibrahim T, Mahboub B, Haider S, Noibi S, Levy G, Al-Lehebi RO
doi: 10.1007/s12325-025-03338-w
RECOMMENDED
Pulmonary Fibrosis
Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros
Højte C, Olsen MF, Faurholt-Jepsen D, Jørgensen MH, Pressler T, Leo-Hansen C, Bryrup T, Jeppesen M, Olesen HV, Petersen J, Katzenstein TL, Nielsen BU, Skov M, TransformCF Study Group
doi: 10.1016/j.jcf.2025.08.008
Asthma
Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study
Adv Ther
Lugogo NL, Akuthota P, Sumino K, Mathur SK, Burnette AF, Lindsley AW, Llanos JP, Marchese C, Ambrose CS, Emmanuel B
doi: 10.1007/s12325-025-03231-6
Pulmonary Fibrosis
Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study
J Clin Med
Lucca F, Meneghelli I, Tridello G, Buniotto F, Cucchetto G, Volpi S, Pintani E, Bezzerri V, Cipolli M
doi: 10.3390/jcm14124335